IL6 and neoplasm: SLC39A1 is also reported to suppress tumour growth in prostate cancer by inhibiting NF‐κB and Ras pathways, leading to decreased levels of apoptotic‐inhibitory factors Bcl‐2/XL and tumorigenic cytokines IL‐6/8.33